USPTO Grants Reissuance Of Lovenox Patent

Law360, New York (December 20, 2004, 12:00 AM EST) -- Three’s the charm for French drug maker Sanofi-Aventis, whose bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally has won approval from the U.S. Patent and Trademark office.

The USPTO previously rejected two attempts to file an application to reissue the patent.

The drug maker said a new U.S. patent for Lovenox could be issued by mid-2005. During the reissuance process, the current patent remains in force but will be replaced by the new patent when it is issued. The...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.